Blueprint Medicines (Blueprint Medicines) Price-to-Operating-Cash-Flow

: (As of Today)

View and export this data going back to 2015. Start your Free Trial

As of today (2024-04-19), Blueprint Medicines's share price is $86.99. Blueprint Medicines's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-7.22. Hence, Blueprint Medicines's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for Blueprint Medicines's Price-to-Operating-Cash-Flow or its related term are showing as below:

During the past 11 years, Blueprint Medicines's highest Price-to-Operating-Cash-Flow Ratio was 20.25. The lowest was 11.39. And the median was 14.83.

BPMC's Price-to-Operating-Cash-Flow is not ranked ^*
in the Biotechnology industry.
Industry Median: 24.39
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

Blueprint Medicines's Cash Flow from Operations per share for the three months ended in Dec. 2023 was $-1.30. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-7.22.

During the past 11 years, Blueprint Medicines's highest 3-Year average Operating Cash Flow per Share Growth Rate was 15.00% per year. The lowest was -86.80% per year. And the median was -10.90% per year.

Blueprint Medicines Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Blueprint Medicines's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Blueprint Medicines Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Operating-Cash-Flow

16.27

Blueprint Medicines Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Operating-Cash-Flow																-	-	-	-	-

Competitive Comparison

For the Biotechnology subindustry, Blueprint Medicines's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Blueprint Medicines Price-to-Operating-Cash-Flow Distribution

For the Biotechnology industry and Healthcare sector, Blueprint Medicines's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Blueprint Medicines's Price-to-Operating-Cash-Flow falls into.

Blueprint Medicines Price-to-Operating-Cash-Flow Calculation

Blueprint Medicines's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	86.99	/	-7.219
	=

Blueprint Medicines's Share Price of today is $86.99.
Blueprint Medicines's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.22.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

Blueprint Medicines Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Blueprint Medicines's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Blueprint Medicines (Blueprint Medicines) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Blueprint Medicines Corp (NAS:BPMC) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

2L9:Germany 2L9:Germany

Address

45 Sidney Street, Cambridge, MA, USA, 02139

Website

https://www.blueprintmedicines.com

Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants.

Executives

Ariel Hurley	officer: Principal Accounting Officer	C/O BLUEPRINT MEDICINES CORPORATION, 45 SIDNEY STREET, CAMBRIDGE MA 02139
Jeffrey W. Albers	director, officer: CEO & President	BLUEPRINT MEDICINES CORP., 215 FIRST STREET, SUITE 340/350, CAMBRIDGE MA 02142
Christopher K. Murray	officer: SVP, Technical Operations	C/O BLUEPRINT MEDICINES CORPORATION, 38 SIDNEY STREET, SUITE 200, CAMBRIDGE MA 02139
Fouad Namouni	officer: President, R and D	535 BOYLSTON ST., 2ND FLOOR, BOSTON MA 02116
L. Becker Hewes	officer: Chief Medical Officer	C/O BLUEPRINT MEDICINES, CORPORATION, CAMBRIDGE MA 02139
Percy H. Carter	officer: Chief Scientific Officer	C/O BLUEPRINT MEDICINES CORPORATION, 45 SIDNEY STREET, CAMBRIDGE MA 02139
Philina Lee	officer: Chief Commercial Officer	C/O FUSION PHARMACEUTICALS, INC., 270 LONGWOOD ROAD SOUTH, HAMILTON D0 L8P OA6
Christina Rossi	officer: Chief Commercial Officer	45 SIDNEY STREET, BLUEPRINT MEDICINES CORPORATION, CAMBRIDGE MA 02139
Tracey L Mccain	officer: EVP and Chief Legal Officer	C/O BLUEPRINTS MEDICINES CORPORATION, 38 SIDNEY STREET, SUITE 200, CAMBRIDGE MA 02139
Michael Landsittel	officer: Principal FAO	BLUEPRINT MEDICINES CORP., 214 FIRST STREET, SUITE 340/350, CAMBRIDGE MA 02142
Debra Durso-bumpus	officer: Chief People Officer	C/O BLUEPRINT MEDICINES CORORATION, 45 SIDNEY STREET, CAMBRIDGE MA 02139
Kate Haviland	officer: Chief Business Officer	BLUEPRINT MEDICINES CORPORATION, 38 SIDNEY STREET, SUITE 200, CAMBRIDGE MA 02139
John Tsai	director	BLUEPRINT MEDICINES CORPORATION, 45 SIDNEY STREET, CAMBRIDGE MA 02139
Habib J Dable	director	C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
George Demetri	director	BLUEPRINT MEDICINES CORP., 215 FIRST STREET, SUITE 340/350, CAMBRIDGE MA 02142